| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Common Stock | Sale | -$868K | -32.2K | -0.59% | $27.00 | 5.4M | Sep 28, 2021 | See Footnote | F1, F2, F3, F4, F5 |
| transaction | ITOS | Common Stock | Sale | -$104K | -3.84K | -0.07% | $27.00 | 5.39M | Sep 30, 2021 | See Footnote | F1, F6, F7, F8 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. |
| F2 | The shares were sold as follows: 11,447 by MPM BioVentures 2014, L.P. ("BV 2014"), 394 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,230 by MPM BioVentures 2018, L.P. ("BV 2018"), 143 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 12,940 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. |
| F3 | BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The shares are held as follows: 1,864,079 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,160 by AM BV2014, 1,177,311 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,235 by AM BV2018 and 2,107,092 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F6 | The shares were sold as follows: 1,366 by BV 2014, 47 by AM BV2014, 862 by BV 2018, 17 by AM BV2018 and 1,544 by UBS Oncology. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.955 to $27.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The shares are held as follows: 1,862,713 by BV 2014, 107,713 by BV 2014(B), 64,113 by AM BV2014, 1,176,449 by BV 2018, 54,213 by BV 2018(B), 23,218 by AM BV2018 and 2,105,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |